Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Celldex Therapeutics, Inc.
A clinical-stage biotechnology company that makes antibody-based medicines designed to calm overactive immune responses behind inflammatory, allergic, and autoimmune conditions. Its lead drug candidate, barzolvolimab, targets a receptor on mast cells to treat chronic hives and other mast-cell-driven diseases. The company was born in 2008 when AVANT Immunotherapeutics merged with a private firm, and its name blends "cell" with the pharma-style "-dex" suffix.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits